Xuebijing and somatostatin against acute pancreatitis: A systematic review and network pharmacology

Acute pancreatitis (AP) is a common pancreatic disease. Xuebijing injection (XBJ) combined with somatostatin in the treatment of AP is frequently used in clinical practice. There is, however, a lack of high-quality evidence-based evidence and network pharmacology to regard the therapeutic efficacy a...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2024-12, Vol.103 (50), p.e40964
Main Authors: Cao, Ji-Ping, Piao, Xiang-Hua, Zhu, Long-Xun, Feng, Pan-Feng
Format: Article
Language:English
Subjects:
Acute Disease
Drug Therapy, Combination
Drugs, Chinese Herbal - pharmacology
Drugs, Chinese Herbal - therapeutic use
Humans
Network Pharmacology - methods
Pancreatitis - drug therapy
Randomized Controlled Trials as Topic
Somatostatin - pharmacology
Somatostatin - therapeutic use
Systematic Review and Meta-Analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute pancreatitis (AP) is a common pancreatic disease. Xuebijing injection (XBJ) combined with somatostatin in the treatment of AP is frequently used in clinical practice. There is, however, a lack of high-quality evidence-based evidence and network pharmacology to regard the therapeutic efficacy and pharmacological mechanisms. The purpose of this study is to investigate the potential therapeutic targets and pharmacological mechanism of XBJ in AP using integrating evidence-based medicine and network pharmacology. PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Weipu, and Wanfang databases were searched. Randomized controlled trials of XBJ combined with somatostatin (experimental group) versus somatostatin alone (control group) in the treatment of AP were collected. After extracting data from the literature that meets the inclusion criteria, and using the Cochrane Scale to evaluate the quality of the literature, we used Rev Man 5.3.0 statistical software to perform meta-analysis of the effective rate, the disappearance time of abdominal pain and bloating, the recovery of gastrointestinal motility, serum-related indicators, inflammatory factors, ventilator evacuation time, and hospitalization time. A network pharmacology is used to analyze the potential active ingredients and related crucial targets of the XBJ in the treatment of AP, and we explored key regulatory pathways and potential biomarkers related to XBJ for AP with integrated bioinformatics analysis. It was significant that the total effective rate in the study group was higher than that in the control group (P 
ISSN:1536-5964
0025-7974
1536-5964
DOI:10.1097/MD.0000000000040964